Madrigal Pharmaceuticals Inc. released its financial results for the first quarter of 2025, reporting net sales of $137.3 million for its product Rezdiffra™ (resmetirom), a significant development as no product sales were recognized during the comparable prior year period. The company's operating expenses increased to $216.6 million from $152.0 million in the previous year. Interest income rose to $9.4 million from $8.3 million, primarily due to higher principal balances, while interest expense decreased to $3.3 million from $3.8 million due to lower interest rates. As of March 31, 2025, Madrigal held $848.1 million in cash, cash equivalents, restricted cash, and marketable securities, a decrease from $931.3 million at the end of 2024, attributed to funding operations. Additionally, Madrigal appointed Dr. David Soergel as Chief Medical Officer and Dr. Rebecca Taub as Senior Scientific and Medical Advisor, with Dr. Jacqualyn Fouse joining the Board of Directors. The company also highlighted that data from its MAESTRO-NAFLD-1 trial has been selected for presentation at the upcoming EASL Congress.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.